Edition:
India

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

38.35USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$38.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
177,846
52-wk High
$50.03
52-wk Low
$24.65

Chart for

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $2,149.64
Shares Outstanding(Mil.): 50.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Supernus announces third quarter 2017 financial results

* Q3 earnings per share view $0.27 -- Thomson Reuters I/B/E/S

07 Nov 2017

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $60.17 --
AstraZeneca plc (AZN.L) 4,713.00 +0.50
Eli Lilly and Co (LLY.N) $78.97 --
Shire PLC (SHP.L) 3,051.00 -59.50
Shire PLC (3159084.L) -- --
Smiths Group plc (SMIN.L) 1,586.50 +16.50

Earnings vs. Estimates